Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F-18-PSMA-1007 vs F-18-Fluorocholine in Prostate Cancer Recurrence
NCT04102553Phase 3Completed
- Sponsor
- ABX advanced biochemical compounds
- Start
- Mar 2019
- Primary completion
- Oct 2020
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by ABX advanced biochemical compounds. Primary endpoint: Detection rate of metastatic prostate cancer lesions. Started Mar 2019; status: completed.
Beyond the preview
Go deeper on NCT04102553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04102553.